Trial Profile
Phase II Study With Trabectedin (Yondelis) in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Advanced Ovarian Cancer Patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 30 Jan 2013 New trial record